Faeth Therapeutics reports Q3 2026 financial results

Item 2.02

Results of Operations and Financial Condition.

On November 3, 2026, Faeth Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2026.^{1 1}A copy of the press release is attached hereto as Exhibit 99.1.¹

The information in this Item 2.02 and the exhibit attached hereto are being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether filed before or after the date hereof and regardless of any general incorporation language in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

Exhibit

Number

Exhibit Description

99.1

Press Release of Faeth Therapeutics, Inc., dated November 3, 2026

104

The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Faeth Therapeutics, Inc.

Date: November 3, 2026

/s/ Christopher W. Gerry

Christopher W. Gerry

General Counsel and Secretary

3

Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates

•

Topline results from the Phase 2 PIK-201 trial in endometrial cancer expected by year-end²

•

FDA granted Fast Track designation to PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer³

•

Presented preclinical data on PIKTOR in HR+/HER2- breast cancer models at ESMO 2026⁴

AUSTIN, Texas—(BUSINESS WIRE)—November 3, 2026— Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced financial results for the quarter ended September 30, 2026, and highlighted recent corporate accomplishments and 2026 milestones.

"Since our last quarterly update, we presented PK/PD analysis that informed the PIKTOR dose in our Phase 2

PIK-201 trial and received Fast Track designation for PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer," said Anand Parikh, Chief Executive Officer. "The PAM pathway is dysregulated in up to 50% of solid tumors, and feedback reactivation and resistance mutations may limit single-node inhibitors. We designed PIKTOR, an all-oral, multi-node inhibitor, to address those limitations, and we believe it has the potential to give patients a differentiated treatment option. We look forward to reading out topline data from ou